Literature DB >> 15115511

Urinary leukotriene E4 correlates with severity of atopic dermatitis in children.

K L E Hon1, T F Leung, K C Ma, A M Li, Y Wong, C Y Li, I H S Chan, T F Fok.   

Abstract

Leukotriene E4 (LTE(4)) is elevated in adults with atopic dermatitis (AD). We evaluated whether urinary LTE(4) as a noninvasive marker correlates with clinical indices of disease activity in children with AD. AD patients aged 18 years or younger were eligible for inclusion in the study. Disease severity over the preceding 3 days was evaluated by the SCORing Atopic Dermatitis (SCORAD) index. Severity of AD over the past 12 months was evaluated by the Nottingham Eczema Severity Score (NESS) in Chinese. Urinary LTE(4) concentration was measured by competitive enzyme immunoassay. One hundred and twenty-six children with AD (82 boys and 44 girls) and 45 controls were recruited. The mean +/- SD urinary log-transformed LTE(4) concentration in AD patients and controls was 2.94 +/- 0.32 and 2.62 +/- 0.20 pg/mg creatinine, respectively (P < 0.0001). SCORAD significantly correlated with NESS (r = 0.681, P < 0.0001). There were significant correlations between urinary LTE(4) concentration and overall SCORAD score (r = 0.270, P = 0.002) and its extent (r = 0.185, P = 0.038) and intensity components (r = 0.247, P = 0.005), but not with NESS. When compared with mild AD, urinary LTE(4) concentrations were higher in patients with moderate-to-severe disease (P = 0.049). Urinary LTE(4) measurement is noninvasive and may be useful in supplementing the SCORAD for following longitudinal changes in AD severity in children. However, the practical value of this assay in a clinical setting remains to be determined.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15115511     DOI: 10.1111/j.1365-2230.2004.01512.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  3 in total

1.  CDLQI, SCORAD and NESS: are they correlated?

Authors:  K L E Hon; W Y C Kam; M C A Lam; T F Leung; P C Ng
Journal:  Qual Life Res       Date:  2006-07-07       Impact factor: 4.147

2.  A systematic review on the off-label use of montelukast in atopic dermatitis treatment.

Authors:  Weng Khong Chin; Shaun Wen Huey Lee
Journal:  Int J Clin Pharm       Date:  2018-05-18

3.  A Double-Blind, Randomized, Crossover Study to Compare the Effectiveness of Montelukast on Atopic Dermatitis in Korean Children.

Authors:  You Hoon Jeon; Taek Ki Min; Hyeon Jong Yang; Bok Yang Pyun
Journal:  Allergy Asthma Immunol Res       Date:  2016-07       Impact factor: 5.764

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.